Sign In
Buy ITCI
$131.87
+0 (+0%)
At Close: Jul 01, 2025
Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?
12:37pm, Friday, 29'th Nov 2024
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
08:00am, Tuesday, 19'th Nov 2024
BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for cent
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
08:00am, Thursday, 07'th Nov 2024
Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial
07:14am, Tuesday, 05'th Nov 2024
Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.
Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript
01:34pm, Wednesday, 30'th Oct 2024
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder,
ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
12:06pm, Wednesday, 30'th Oct 2024
Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
09:40am, Wednesday, 30'th Oct 2024
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.25 per share a year ago.
Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
07:30am, Wednesday, 30'th Oct 2024
CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Wednesday, 23'rd Oct 2024
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
08:00am, Thursday, 17'th Oct 2024
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
11:30am, Friday, 11'th Oct 2024
ITCI is seeing strong Caplyta sales, driven by a high prescription rate. However, its heavy reliance on the drug's sales for growth is concerning.
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
08:00am, Monday, 23'rd Sep 2024
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
12:37pm, Friday, 06'th Sep 2024
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
08:00am, Wednesday, 28'th Aug 2024
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv
Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon
11:06am, Thursday, 08'th Aug 2024
This biotech stock is in a base and seeking support at a moving average. The company's losses are dwindling and analysts see profits coming.
